Obesity and myeloma: Clinical and mechanistic contributions to disease progression
Document Type
Article
Publication Date
2-23-2023
Institution/Department
Endocrinology & Diabetes
Journal Title
Frontiers in Endocrinology
MeSH Headings
Humans; Multiple Myeloma (complications, pathology); Obesity (complications); Monoclonal Gammopathy of Undetermined Significance (complications, pathology); Bone Marrow (pathology); Disease Progression; Tumor Microenvironment
Abstract
Obesity and obesogenic behaviors are positively associated with both monoclonal gammopathy of unknown significance (MGUS) and multiple myeloma (MM). As the only known modifiable risk factor, this association has emerged as a new potential target for MM prevention, but little is known about the mechanistic relationship of body weight with MM progression. Here we summarize epidemiological correlations between weight, body composition, and the various stages of myeloma disease progression and treatments, as well as the current understanding of the molecular contributions of obesity-induced changes in myeloma cell phenotype and signaling. Finally, we outline groundwork for the future characterization of the relationship between body weight patterns, the bone marrow microenvironment, and MM pathogenesis in animal models, which have the potential to impact our understanding of disease pathogenesis and inform MM prevention messages.
ISSN
1664-2392
First Page
1118691
Recommended Citation
Marques-Mourlet C, Di Iorio R, Fairfield H, Reagan MR. Obesity and myeloma: Clinical and mechanistic contributions to disease progression. Front Endocrinol (Lausanne). 2023;14:1118691. Published 2023 Feb 23. doi:10.3389/fendo.2023.1118691